Drug Insight: statins and gastrointestinal cancer
| Autor: | Peter D.R. Higgins, Taft P. Bhuket |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Drug
medicine.medical_specialty Cost-Benefit Analysis media_common.quotation_subject Drug Costs Basic research medicine Humans cardiovascular diseases Gastrointestinal cancer Intensive care medicine Gastrointestinal Neoplasms media_common Hepatology business.industry Liver Neoplasms Gastroenterology nutritional and metabolic diseases General Medicine medicine.disease Cancer treatment Pancreatic Neoplasms Biliary Tract Neoplasms Clinical research lipids (amino acids peptides and proteins) Observational study Hydroxymethylglutaryl-CoA Reductase Inhibitors business |
| Zdroj: | Nature Clinical Practice Gastroenterology & Hepatology. 3:552-562 |
| ISSN: | 1743-4386 1743-4378 |
| DOI: | 10.1038/ncpgasthep0603 |
| Popis: | Statins are popular lipid-lowering drugs that have had a great impact on the primary and secondary prevention of cardiovascular diseases. Basic and clinical research have also revealed that statins have biologic activities that go beyond lipid lowering, and suggest that they might have other therapeutic benefits. Perhaps the most exciting of these additional biologic effects is the finding that statins can exert an anticancer effect on cultured cancer cells, and in animal models. Clinical studies of statins for the treatment and prevention of cancer have, however, produced conflicting results. This review critically evaluates the current body of literature on the role of statins in the treatment and prevention of gastrointestinal cancers, with particular focus on clinical and observational studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink